PACTG 1006: EFFECTS OF HAART ON THE RECOVERY OF IMMUNE FUNCTION IN HIV+ CHILDREN
PACTG 1006:HAART 对 HIV 儿童免疫功能恢复的影响
基本信息
- 批准号:7605689
- 负责人:
- 金额:$ 3.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-01 至 2008-03-31
- 项目状态:已结题
- 来源:
- 关键词:Antibody FormationAntigensCD4 Lymphocyte CountCD4 Positive T LymphocytesCandidaCell CountChildChildhoodComputer Retrieval of Information on Scientific Projects DatabaseFundingGrantGrowthHIVHepatitis AHepatitis A immunizationHighly Active Antiretroviral TherapyImmuneImmunizationImmunocompromised HostImmunologicsInstitutionMeasuresNatural regenerationNumbersPhenotypePlasmaPopulationPurposeRNARandomizedRecoveryRecovery of FunctionResearchResearch PersonnelResourcesSecondary ImmunizationSeriesSerologicalSourceT-LymphocyteTestingTetanusTetanus ToxoidTetanus VaccineTranslatingUnited States National Institutes of HealthVaccinationagedcell mediated immune responsecomparativefollow-upimmune functionresponsetreatment duration
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
This study is a randomized, comparative response study with long-term follow-up in HIV-infected children aged 2-17 years who are severely immunocompromised and are initiating highly active antiretroviral therapy (HAART). Subjects must be virologic responders, defined as >0.75 log decrease in plasma HIV RNA copy number 1 month after initiation of HAART. It will consist of approximately 90 subjects in two groups. The purpose of this study is to assess the ability of newly derived CD4 T cells to spontaneously develop lymphoproliferative responses to a recall antigen, tetanus toxoid, or to develop responses after booster vaccinations with tetanus vaccine; to assess the ability to develop protective antibody responses to a T cell-dependent antigen using a primary series of hepatitis A vaccinations.; and to measure the durability of any response beyond the last vaccination.
The rationale for this study is that HIV-infected children initiating HAART have shown significant inhibition of HIV growth and significant increases in CD4 T cell counts. It is not known to what extent an increase in CD4 count in this population of children translates to a complete functional immune recovery. HIV-infected children have typically demonstrated poor serological responses to routine childhood immunizations. This study will examine the phenotype of T cells regenerated post-HAART initiation and will assess function by evaluating T cell responses to neoantigens and recall antigens. Cell-mediated immune responses to an environmental antigen (Candida), a recall antigen (tetanus), and a primary immunogen (hepatitis A) will be tested. Studies of immunologic function and recovery will be assessed and correlated with CD4 cells, HAART treatment, and duration of response.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William Borkowsky其他文献
William Borkowsky的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William Borkowsky', 18)}}的其他基金
CLINICAL TRIAL: PACTG 390: ANTIRETROVIRAL REGIMENS AND TREATMENT-SWITCHING STRAT
临床试验:PACTG 390:抗逆转录病毒治疗方案和治疗转换策略
- 批准号:
7718416 - 财政年份:2008
- 资助金额:
$ 3.73万 - 项目类别:
CLINICAL TRIAL: PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFEC
临床试验:PACTG 1020-A:用于 HIV-INFEC 的新型蛋白酶抑制剂 (BMS-232632)
- 批准号:
7718391 - 财政年份:2008
- 资助金额:
$ 3.73万 - 项目类别:
CLINICAL TRIAL: PACTG 1025: PERINATAL CORE PROTOCOL (AIDS)
临床试验:PACTG 1025:围产期核心方案(艾滋病)
- 批准号:
7718399 - 财政年份:2008
- 资助金额:
$ 3.73万 - 项目类别:
CLINICAL TRIAL: ACTG 219: PEDIATRIC LATE OUTCOMES (AIDS)
临床试验:ACTG 219:儿科晚期结果(艾滋病)
- 批准号:
7718380 - 财政年份:2008
- 资助金额:
$ 3.73万 - 项目类别:
PACTG 390: ANTIRETROVIRAL REGIMENS AND TREATMENT-SWITCHING STRATEGIES (AIDS)
PACTG 390:抗逆转录病毒治疗方案和治疗转换策略(艾滋病)
- 批准号:
7605729 - 财政年份:2007
- 资助金额:
$ 3.73万 - 项目类别:
PACTG 1025: PERINATAL CORE PROTOCOL (AIDS)
PACTG 1025:围产期核心方案(艾滋病)
- 批准号:
7605703 - 财政年份:2007
- 资助金额:
$ 3.73万 - 项目类别:
PACTG P1038: LOPINAVIR/RITONAVIR IN PEDIATRIC SUBJECTS WITH HIV PREVIOUSLY TREAT
PACTG P1038:洛匹那韦/利托那韦用于既往治疗的艾滋病毒儿科患者
- 批准号:
7605739 - 财政年份:2007
- 资助金额:
$ 3.73万 - 项目类别:
PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFECTED CHILDREN
PACTG 1020-A:用于 HIV 感染儿童的新型蛋白酶抑制剂 (BMS-232632)
- 批准号:
7605692 - 财政年份:2007
- 资助金额:
$ 3.73万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 3.73万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 3.73万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 3.73万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 3.73万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 3.73万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 3.73万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 3.73万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 3.73万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 3.73万 - 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 3.73万 - 项目类别: